VERTEX PHARMACEUTICALS INC / MA Insider Trading for February 2021
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in VERTEX PHARMACEUTICALS INC / MA.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in VERTEX PHARMACEUTICALS INC / MA for February 2021.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Chief Account ... | Sell | S | 216.25 | 126 | 27,248 | 14,884 | 15 K to 14.9 K (-0.84 %) |
| Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Chief Account ... | Sell | S | 214.32 | 258 | 55,295 | 15,010 | 15.3 K to 15 K (-1.69 %) |
| Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Chief Account ... | Sell | S | 213.12 | 452 | 96,330 | 15,268 | 15.7 K to 15.3 K (-2.88 %) |
| Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Chief Account ... | Sell | S | 211.80 | 244 | 51,679 | 15,720 | 16 K to 15.7 K (-1.53 %) |
| Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Chief Account ... | Payment of Exercise | F | 217.57 | 864 | 187,980 | 15,964 | 16.8 K to 16 K (-5.13 %) |
| Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, Chief Patient ... | Sell | S | 216.62 | 200 | 43,324 | 40,133 | 40.3 K to 40.1 K (-0.50 %) |
| Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, Chief Patient ... | Sell | S | 215.56 | 336 | 72,428 | 40,333 | 40.7 K to 40.3 K (-0.83 %) |
| Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, Chief Patient ... | Sell | S | 214.19 | 668 | 143,079 | 40,669 | 41.3 K to 40.7 K (-1.62 %) |
| Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, Chief Patient ... | Sell | S | 213.30 | 1,460 | 311,418 | 41,337 | 42.8 K to 41.3 K (-3.41 %) |
| Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, Chief Patient ... | Sell | S | 211.56 | 922 | 195,058 | 42,797 | 43.7 K to 42.8 K (-2.11 %) |
| Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, Chief Patient ... | Payment of Exercise | F | 217.57 | 2,946 | 640,961 | 43,719 | 46.7 K to 43.7 K (-6.31 %) |
| Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, Chief Adm, Leg ... | Sell | S | 216.26 | 354 | 76,556 | 30,837 | 31.2 K to 30.8 K (-1.13 %) |
| Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, Chief Adm, Leg ... | Sell | S | 214.28 | 680 | 145,710 | 31,191 | 31.9 K to 31.2 K (-2.13 %) |
| Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, Chief Adm, Leg ... | Sell | S | 213.04 | 1,348 | 287,178 | 31,871 | 33.2 K to 31.9 K (-4.06 %) |
| Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, Chief Adm, Leg ... | Sell | S | 211.58 | 646 | 136,681 | 33,219 | 33.9 K to 33.2 K (-1.91 %) |
| Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, Chief Adm, Leg ... | Payment of Exercise | F | 217.57 | 2,416 | 525,649 | 33,865 | 36.3 K to 33.9 K (-6.66 %) |
| Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Payment of Exercise | F | 217.57 | 2,898 | 630,518 | 63,643 | 66.5 K to 63.6 K (-4.36 %) |
| Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | Bozic Carmen | EVP and CMO | Payment of Exercise | F | 217.57 | 311 | 67,664 | 33,264 | 33.6 K to 33.3 K (-0.93 %) |
| Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 216.57 | 254 | 55,009 | 41,103 | 41.4 K to 41.1 K (-0.61 %) |
| Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 215.62 | 300 | 64,686 | 41,357 | 41.7 K to 41.4 K (-0.72 %) |
| Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 214.32 | 400 | 85,728 | 41,657 | 42.1 K to 41.7 K (-0.95 %) |
| Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 213.55 | 1,400 | 298,970 | 42,057 | 43.5 K to 42.1 K (-3.22 %) |
| Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 212.52 | 900 | 191,268 | 43,457 | 44.4 K to 43.5 K (-2.03 %) |
| Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 211.39 | 380 | 80,328 | 44,357 | 44.7 K to 44.4 K (-0.85 %) |
| Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Payment of Exercise | F | 217.57 | 2,898 | 630,518 | 44,737 | 47.6 K to 44.7 K (-6.08 %) |
| Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Sell | S | 216.26 | 354 | 76,556 | 33,589 | 33.9 K to 33.6 K (-1.04 %) |
| Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Sell | S | 214.28 | 680 | 145,710 | 33,943 | 34.6 K to 33.9 K (-1.96 %) |
| Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Sell | S | 213.05 | 1,348 | 287,191 | 34,623 | 36 K to 34.6 K (-3.75 %) |
| Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Sell | S | 211.58 | 646 | 136,681 | 35,971 | 36.6 K to 36 K (-1.76 %) |
| Feb 26 2021 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Payment of Exercise | F | 217.57 | 2,416 | 525,649 | 36,617 | 39 K to 36.6 K (-6.19 %) |
| Feb 19 2021 | VRTX | VERTEX PHARMACEUTI ... | Tatsis Ourania | EVP, Chief Reg. & Q ... | Payment of Exercise | F | 211.75 | 2,000 | 423,500 | 32,468 | 34.5 K to 32.5 K (-5.80 %) |
| Feb 19 2021 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Chief Account ... | Sell | S | 212.62 | 1,368 | 290,864 | 16,828 | 18.2 K to 16.8 K (-7.52 %) |
| Feb 19 2021 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Chief Account ... | Sell | S | 211.82 | 2,343 | 496,294 | 18,196 | 20.5 K to 18.2 K (-11.41 %) |
| Feb 19 2021 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Chief Account ... | Sell | S | 210.05 | 584 | 122,669 | 20,539 | 21.1 K to 20.5 K (-2.76 %) |
| Feb 19 2021 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Chief Account ... | Payment of Exercise | F | 211.75 | 2,740 | 580,195 | 21,123 | 23.9 K to 21.1 K (-11.48 %) |
| Feb 19 2021 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, Chief Patient ... | Sell | S | 213.02 | 800 | 170,416 | 46,665 | 47.5 K to 46.7 K (-1.69 %) |
| Feb 19 2021 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, Chief Patient ... | Sell | S | 212.15 | 5,800 | 1,230,470 | 47,465 | 53.3 K to 47.5 K (-10.89 %) |
| Feb 19 2021 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, Chief Patient ... | Sell | S | 211.36 | 1,500 | 317,040 | 53,265 | 54.8 K to 53.3 K (-2.74 %) |
| Feb 19 2021 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, Chief Patient ... | Sell | S | 210.00 | 1,164 | 244,440 | 54,765 | 55.9 K to 54.8 K (-2.08 %) |
| Feb 19 2021 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, Chief Patient ... | Payment of Exercise | F | 211.75 | 7,613 | 1,612,053 | 55,929 | 63.5 K to 55.9 K (-11.98 %) |
| Feb 19 2021 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, Chief Adm, Leg ... | Sell | S | 213.45 | 200 | 42,690 | 36,281 | 36.5 K to 36.3 K (-0.55 %) |
| Feb 19 2021 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, Chief Adm, Leg ... | Sell | S | 212.56 | 1,952 | 414,917 | 36,481 | 38.4 K to 36.5 K (-5.08 %) |
| Feb 19 2021 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, Chief Adm, Leg ... | Sell | S | 211.83 | 4,666 | 988,399 | 38,433 | 43.1 K to 38.4 K (-10.83 %) |
| Feb 19 2021 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, Chief Adm, Leg ... | Sell | S | 210.08 | 1,007 | 211,551 | 43,099 | 44.1 K to 43.1 K (-2.28 %) |
| Feb 19 2021 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, Chief Adm, Leg ... | Payment of Exercise | F | 211.75 | 6,240 | 1,321,320 | 44,106 | 50.3 K to 44.1 K (-12.39 %) |
| Feb 19 2021 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Payment of Exercise | F | 211.75 | 2,080 | 440,440 | 66,541 | 68.6 K to 66.5 K (-3.03 %) |
| Feb 19 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 213.26 | 100 | 21,326 | 47,635 | 47.7 K to 47.6 K (-0.21 %) |
| Feb 19 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 212.49 | 2,763 | 587,110 | 47,735 | 50.5 K to 47.7 K (-5.47 %) |
| Feb 19 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 211.77 | 3,940 | 834,374 | 50,498 | 54.4 K to 50.5 K (-7.24 %) |
| Feb 19 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 210.05 | 1,022 | 214,671 | 54,438 | 55.5 K to 54.4 K (-1.84 %) |
| Feb 19 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Payment of Exercise | F | 211.75 | 6,240 | 1,321,320 | 55,460 | 61.7 K to 55.5 K (-10.11 %) |
| Feb 19 2021 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Sell | S | 213.26 | 200 | 42,652 | 39,033 | 39.2 K to 39 K (-0.51 %) |
| Feb 19 2021 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Sell | S | 212.59 | 2,033 | 432,195 | 39,233 | 41.3 K to 39.2 K (-4.93 %) |
| Feb 19 2021 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Sell | S | 211.84 | 4,513 | 956,034 | 41,266 | 45.8 K to 41.3 K (-9.86 %) |
| Feb 19 2021 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Sell | S | 210.11 | 1,079 | 226,709 | 45,779 | 46.9 K to 45.8 K (-2.30 %) |
| Feb 19 2021 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Payment of Exercise | F | 211.75 | 6,240 | 1,321,320 | 46,858 | 53.1 K to 46.9 K (-11.75 %) |
| Feb 16 2021 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Chief Account ... | Sell | S | 211.32 | 210 | 44,377 | 23,863 | 24.1 K to 23.9 K (-0.87 %) |
| Feb 16 2021 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Chief Account ... | Sell | S | 210.45 | 1,288 | 271,060 | 24,073 | 25.4 K to 24.1 K (-5.08 %) |
| Feb 12 2021 | VRTX | VERTEX PHARMACEUTI ... | Tatsis Ourania | EVP, Chief Reg. & Q ... | Payment of Exercise | F | 214.16 | 1,230 | 263,417 | 34,468 | 35.7 K to 34.5 K (-3.45 %) |
| Feb 12 2021 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, Chief Patient ... | Payment of Exercise | F | 214.16 | 2,421 | 518,481 | 68,002 | 70.4 K to 68 K (-3.44 %) |
| Feb 12 2021 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Payment of Exercise | F | 214.16 | 2,974 | 636,912 | 58,381 | 61.4 K to 58.4 K (-4.85 %) |
| Feb 09 2021 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, Chief Adm, Leg ... | Option Exercise | M | 86.52 | 1,930 | 166,984 | 0 | |
| Feb 09 2021 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, Chief Adm, Leg ... | Sell | S | 215.00 | 1,930 | 414,950 | 57,227 | 59.2 K to 57.2 K (-3.26 %) |
| Feb 09 2021 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, Chief Adm, Leg ... | Buy | M | 86.52 | 1,930 | 166,984 | 59,157 | 57.2 K to 59.2 K (+3.37 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Tatsis Ourania | EVP, Chief Reg. & Q ... | Grant | A | 0.00 | 13,952 | 0 | 35,698 | 21.7 K to 35.7 K (+64.16 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Tatsis Ourania | EVP, Chief Reg. & Q ... | Grant | A | 0.00 | 6,194 | 0 | 21,746 | 15.6 K to 21.7 K (+39.83 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Tatsis Ourania | EVP, Chief Reg. & Q ... | Grant | A | 0.00 | 2,814 | 0 | 15,552 | 12.7 K to 15.6 K (+22.09 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Chief Account ... | Grant | A | 0.00 | 3,634 | 0 | 26,012 | 22.4 K to 26 K (+16.24 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Chief Account ... | Grant | A | 0.00 | 3,226 | 0 | 22,378 | 19.2 K to 22.4 K (+16.84 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Chief Account ... | Grant | A | 0.00 | 4,220 | 0 | 19,152 | 14.9 K to 19.2 K (+28.26 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Sanna Bastiano | EVP, Cell & Genetic ... | Grant | A | 0.00 | 11,627 | 0 | 41,894 | 30.3 K to 41.9 K (+38.41 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Sanna Bastiano | EVP, Cell & Genetic ... | Grant | A | 0.00 | 9,092 | 0 | 30,267 | 21.2 K to 30.3 K (+42.94 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, Chief Patient ... | Grant | A | 0.00 | 11,627 | 0 | 70,423 | 58.8 K to 70.4 K (+19.78 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, Chief Patient ... | Grant | A | 0.00 | 10,324 | 0 | 58,796 | 48.5 K to 58.8 K (+21.30 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, Chief Patient ... | Grant | A | 0.00 | 10,126 | 0 | 48,472 | 38.3 K to 48.5 K (+26.41 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, Chief Patient ... | Gift | G | 0.00 | 3,391 | 0 | 7,368 | 10.8 K to 7.4 K (-31.52 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, Chief Patient ... | Grant | A | 0.00 | 11,627 | 0 | 70,423 | 58.8 K to 70.4 K (+19.78 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, Chief Patient ... | Grant | A | 0.00 | 10,324 | 0 | 58,796 | 48.5 K to 58.8 K (+21.30 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, Chief Patient ... | Grant | A | 0.00 | 10,126 | 0 | 48,472 | 38.3 K to 48.5 K (+26.41 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, Chief Patient ... | Gift | G | 0.00 | 3,391 | 0 | 7,368 | 10.8 K to 7.4 K (-31.52 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, Chief Adm, Leg ... | Option Exercise | M | 86.52 | 400 | 34,608 | 1,930 | |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, Chief Adm, Leg ... | Sell | S | 218.20 | 100 | 21,820 | 57,227 | 57.3 K to 57.2 K (-0.17 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, Chief Adm, Leg ... | Sell | S | 217.00 | 100 | 21,700 | 57,327 | 57.4 K to 57.3 K (-0.17 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, Chief Adm, Leg ... | Sell | S | 215.52 | 200 | 43,104 | 57,427 | 57.6 K to 57.4 K (-0.35 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, Chief Adm, Leg ... | Buy | M | 86.52 | 400 | 34,608 | 57,627 | 57.2 K to 57.6 K (+0.70 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, Chief Adm, Leg ... | Grant | A | 0.00 | 11,627 | 0 | 57,227 | 45.6 K to 57.2 K (+25.50 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, Chief Adm, Leg ... | Grant | A | 0.00 | 10,324 | 0 | 45,600 | 35.3 K to 45.6 K (+29.27 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, Chief Adm, Leg ... | Grant | A | 0.00 | 8,438 | 0 | 35,276 | 26.8 K to 35.3 K (+31.44 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, Chief Adm, Leg ... | Option Exercise | M | 86.52 | 400 | 34,608 | 1,930 | |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, Chief Adm, Leg ... | Sell | S | 218.20 | 100 | 21,820 | 57,227 | 57.3 K to 57.2 K (-0.17 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, Chief Adm, Leg ... | Sell | S | 217.00 | 100 | 21,700 | 57,327 | 57.4 K to 57.3 K (-0.17 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, Chief Adm, Leg ... | Sell | S | 215.52 | 200 | 43,104 | 57,427 | 57.6 K to 57.4 K (-0.35 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, Chief Adm, Leg ... | Buy | M | 86.52 | 400 | 34,608 | 57,627 | 57.2 K to 57.6 K (+0.70 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, Chief Adm, Leg ... | Grant | A | 0.00 | 11,627 | 0 | 57,227 | 45.6 K to 57.2 K (+25.50 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, Chief Adm, Leg ... | Grant | A | 0.00 | 10,324 | 0 | 45,600 | 35.3 K to 45.6 K (+29.27 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, Chief Adm, Leg ... | Grant | A | 0.00 | 8,438 | 0 | 35,276 | 26.8 K to 35.3 K (+31.44 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | Executive Chairman | Payment of Exercise | F | 215.03 | 8,599 | 1,849,043 | 77,600 | 86.2 K to 77.6 K (-9.98 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | Executive Chairman | Grant | A | 0.00 | 20,928 | 0 | 86,199 | 65.3 K to 86.2 K (+32.06 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | Executive Chairman | Grant | A | 0.00 | 31,462 | 0 | 65,271 | 33.8 K to 65.3 K (+93.06 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | Executive Chairman | Grant | A | 0.00 | 31,498 | 0 | 33,809 | 2.3 K to 33.8 K (+1,362.96 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | Executive Chairman | Payment of Exercise | F | 215.03 | 8,599 | 1,849,043 | 77,600 | 86.2 K to 77.6 K (-9.98 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | Executive Chairman | Grant | A | 0.00 | 20,928 | 0 | 86,199 | 65.3 K to 86.2 K (+32.06 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | Executive Chairman | Grant | A | 0.00 | 31,462 | 0 | 65,271 | 33.8 K to 65.3 K (+93.06 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Grant | A | 0.00 | 29,031 | 0 | 71,583 | 42.6 K to 71.6 K (+68.22 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | Executive Chairman | Grant | A | 0.00 | 31,498 | 0 | 33,809 | 2.3 K to 33.8 K (+1,362.96 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Grant | A | 0.00 | 12,388 | 0 | 42,552 | 30.2 K to 42.6 K (+41.07 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Grant | A | 0.00 | 3,516 | 0 | 30,164 | 26.6 K to 30.2 K (+13.19 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Grant | A | 0.00 | 29,031 | 0 | 71,583 | 42.6 K to 71.6 K (+68.22 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Grant | A | 0.00 | 12,388 | 0 | 42,552 | 30.2 K to 42.6 K (+41.07 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | CEO & President | Grant | A | 0.00 | 3,516 | 0 | 30,164 | 26.6 K to 30.2 K (+13.19 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Bozic Carmen | EVP and CMO | Grant | A | 0.00 | 11,627 | 0 | 35,942 | 24.3 K to 35.9 K (+47.82 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Bozic Carmen | EVP and CMO | Grant | A | 0.00 | 10,324 | 0 | 24,315 | 14 K to 24.3 K (+73.79 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Option Exercise | M | 86.52 | 1,554 | 134,452 | 0 | |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Bozic Carmen | EVP and CMO | Grant | A | 0.00 | 11,627 | 0 | 35,942 | 24.3 K to 35.9 K (+47.82 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 216.83 | 89 | 19,298 | 69,957 | 70 K to 70 K (-0.13 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Bozic Carmen | EVP and CMO | Grant | A | 0.00 | 10,324 | 0 | 24,315 | 14 K to 24.3 K (+73.79 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 215.80 | 90 | 19,422 | 70,046 | 70.1 K to 70 K (-0.13 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 214.98 | 242 | 52,025 | 70,136 | 70.4 K to 70.1 K (-0.34 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 213.90 | 497 | 106,308 | 70,378 | 70.9 K to 70.4 K (-0.70 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 212.77 | 488 | 103,832 | 70,875 | 71.4 K to 70.9 K (-0.68 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 211.22 | 148 | 31,261 | 71,363 | 71.5 K to 71.4 K (-0.21 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Buy | M | 86.52 | 1,554 | 134,452 | 71,511 | 70 K to 71.5 K (+2.22 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Grant | A | 0.00 | 13,952 | 0 | 69,957 | 56 K to 70 K (+24.91 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Grant | A | 0.00 | 12,388 | 0 | 56,005 | 43.6 K to 56 K (+28.40 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Option Exercise | M | 86.52 | 1,554 | 134,452 | 0 | |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Grant | A | 0.00 | 8,438 | 0 | 43,617 | 35.2 K to 43.6 K (+23.99 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 216.83 | 89 | 19,298 | 69,957 | 70 K to 70 K (-0.13 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 215.80 | 90 | 19,422 | 70,046 | 70.1 K to 70 K (-0.13 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 214.98 | 242 | 52,025 | 70,136 | 70.4 K to 70.1 K (-0.34 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 213.90 | 497 | 106,308 | 70,378 | 70.9 K to 70.4 K (-0.70 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 212.77 | 488 | 103,832 | 70,875 | 71.4 K to 70.9 K (-0.68 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Sell | S | 211.22 | 148 | 31,261 | 71,363 | 71.5 K to 71.4 K (-0.21 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Buy | M | 86.52 | 1,554 | 134,452 | 71,511 | 70 K to 71.5 K (+2.22 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Grant | A | 0.00 | 13,952 | 0 | 69,957 | 56 K to 70 K (+24.91 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Grant | A | 0.00 | 12,388 | 0 | 56,005 | 43.6 K to 56 K (+28.40 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP, Chief Commerci ... | Grant | A | 0.00 | 8,438 | 0 | 43,617 | 35.2 K to 43.6 K (+23.99 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Grant | A | 0.00 | 11,627 | 0 | 61,355 | 49.7 K to 61.4 K (+23.38 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Grant | A | 0.00 | 12,388 | 0 | 49,728 | 37.3 K to 49.7 K (+33.18 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Grant | A | 0.00 | 8,438 | 0 | 37,340 | 28.9 K to 37.3 K (+29.20 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Grant | A | 0.00 | 11,627 | 0 | 61,355 | 49.7 K to 61.4 K (+23.38 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Grant | A | 0.00 | 12,388 | 0 | 49,728 | 37.3 K to 49.7 K (+33.18 %) |
| Feb 05 2021 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Grant | A | 0.00 | 8,438 | 0 | 37,340 | 28.9 K to 37.3 K (+29.20 %) |